14788

532872

SPARC

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SUN PHARMA ADV.RES.CO.LTD Share Price Today

SUN PHARMA ADV.RES.CO.LTD is currently trading at ₹234.92, down by ₹3.11 from the previous close. The stock touched an intraday high of ₹244.75 and a low of ₹234.00 during the latest trading session. Over the past one year, SUN PHARMA ADV.RES.CO.LTD has delivered a return of 58.07%, while the stock has gained 32.44% in the last one month.

SUN PHARMA ADV.RES.CO.LTD performance

Today’s low Today’s high
₹ 234.00 ₹ 244.75
₹ 236.43
52 week low 52 week high
₹ 108.00 ₹ 253.17
₹ 236.43
Open Price ₹ 237.51
Prev. Close ₹ 238.03
Volume (Shares) 1752027.00
Total traded value ₹ 4142.31
Upper Circuit ₹ 261.83
Lower Circuit ₹ 214.23
info

Investment Returns

Over 1 Month 32.44% Over 3 Months 106.67% Over 6 Months 65.54% Over 1 Year 58.07%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

SUN PHARMA ADV.RES.CO.LTD fundamentals


  • Market cap (Cr) 7,679.50
  • P/E Ratio (TTM) 4.97
  • Beta 1.85
  • Book Value / share 41.09
  • Return on equity 0.00%
  • EPS (TTM) 48.21
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 1,760.70
info icon alternate text
  • Market cap (Cr) 7,670.10
  • P/E Ratio (TTM) 4.97
  • Beta 1.77
  • Book Value / share 41.09
  • Return on equity 0.00%
  • EPS (TTM) 48.21
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 1,760.70
info icon alternate text

SUN PHARMA ADV.RES.CO.LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 13.20
Operating Expense 94.32
Net Profit 1760.70
Net Profit Margin (%) 13338.63
Earnings Per Share (EPS) 54.26
EBITDA 1774.74
Effective Tax Rate (%) 0.00
Particulars DEC 2025 (Values in Cr)
Revenue 8.45
Operating Expense 76.66
Net Profit -80.57
Net Profit Margin (%) -953.49
Earnings Per Share (EPS) -2.48
EBITDA -69.22
Effective Tax Rate (%) 0.00
Particulars SEP 2025 (Values in Cr)
Revenue 7.86
Operating Expense 83.83
Net Profit -75.97
Net Profit Margin (%) -966.53
Earnings Per Share (EPS) -2.34
EBITDA -65.88
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 9.64
Operating Expense 70.69
Net Profit -52.03
Net Profit Margin (%) -539.73
Earnings Per Share (EPS) -1.60
EBITDA -43.31
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 27.19
Operating Expense 88.17
Net Profit -60.98
Net Profit Margin (%) -224.27
Earnings Per Share (EPS) -1.88
EBITDA -53.92
Effective Tax Rate (%) 0.00
Particulars MAR 2026 (Values in Cr)
Revenue 39.15
Operating Expense 325.51
Net Profit 1552.13
Net Profit Margin (%) 3964.57
Earnings Per Share (EPS) 47.83
EBITDA 1596.32
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 71.77
Operating Expense 418.78
Net Profit -345.22
Net Profit Margin (%) -481.00
Earnings Per Share (EPS) -10.64
EBITDA -325.48
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 75.55
Operating Expense 493.13
Net Profit -388.11
Net Profit Margin (%) -513.71
Earnings Per Share (EPS) -11.96
EBITDA -374.32
Effective Tax Rate (%) 0.00
Particulars MAR 2023 (Values in Cr)
Revenue 238.78
Operating Expense 472.24
Net Profit -222.58
Net Profit Margin (%) -93.21
Earnings Per Share (EPS) -7.82
EBITDA -203.18
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 137.25
Operating Expense 347.49
Net Profit -203.40
Net Profit Margin (%) -148.19
Earnings Per Share (EPS) -7.73
EBITDA -179.91
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Book Value / Share -6.68
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -447.75
Particulars MAR 2024 (Values in Cr)
Book Value / Share 3.88
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.12
EBITDA Margin -493.22
Particulars MAR 2023 (Values in Cr)
Book Value / Share 15.80
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.03
EBITDA Margin -85.09
Particulars MAR 2025 (Values in Cr)
Book Value / Share -6.80
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -453.50
Particulars MAR 2024 (Values in Cr)
Book Value / Share 3.85
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.11
EBITDA Margin -495.46
Particulars MAR 2023 (Values in Cr)
Book Value / Share 15.80
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.17
EBITDA Margin -85.09
Particulars MAR 2022 (Values in Cr)
Book Value / Share -7.47
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -131.07
Particulars MAR 2021 (Values in Cr)
Book Value / Share -6.42
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -51.22
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1.96
Total Assets 335.53
Total Liabilities 335.53
Total Equity -216.94
Share Outstanding 32
Price to Book Ratio -21.76
Return on Assets (%) -102.07
Return on Capital (%) -830.58
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 155.32
Total Assets 515.04
Total Liabilities 515.04
Total Equity 125.75
Share Outstanding 32
Price to Book Ratio 96.09
Return on Assets (%) -75.18
Return on Capital (%) -224.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 111.57
Total Assets 830.12
Total Liabilities 830.12
Total Equity 512.77
Share Outstanding 32
Price to Book Ratio 11.36
Return on Assets (%) -26.81
Return on Capital (%) -43.4
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1.18
Total Assets 329.27
Total Liabilities 329.27
Total Equity -220.62
Share Outstanding 32
Price to Book Ratio -21.76
Return on Assets (%) -104.84
Return on Capital (%) -919
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 155.06
Total Assets 486.33
Total Liabilities 486.33
Total Equity 124.85
Share Outstanding 32
Price to Book Ratio 96.09
Return on Assets (%) -79.80
Return on Capital (%) -225.83
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 111.57
Total Assets 830.12
Total Liabilities 830.12
Total Equity 512.77
Share Outstanding 32
Price to Book Ratio 11.36
Return on Assets (%) -26.81
Return on Capital (%) -43.4
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.22
Total Assets 280.08
Total Liabilities 280.08
Total Equity 31.22
Share Outstanding 27
Price to Book Ratio -39.74
Return on Assets (%) -72.61
Return on Capital (%) -191.47
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.31
Total Assets 229.68
Total Liabilities 229.68
Total Equity -168.25
Share Outstanding 26
Price to Book Ratio -22.07
Return on Assets (%) -65.80
Return on Capital (%) -242.62
Particulars MAR 2025 (Values in Cr)
Net Income -342.78
Cash from Operations -369.11
Cash from Investing 157.66
Cash from Financing 199.25
Net change in Cash -3.37
Free Cash Flow -358.78
Particulars MAR 2024 (Values in Cr)
Net Income -386.83
Cash from Operations -425.07
Cash from Investing 391.52
Cash from Financing 42.40
Net change in Cash 4.74
Free Cash Flow -398.56
Particulars MAR 2023 (Values in Cr)
Net Income -222.58
Cash from Operations -74.48
Cash from Investing -548.27
Cash from Financing 616.75
Net change in Cash -0.64
Free Cash Flow -59.09
Particulars MAR 2025 (Values in Cr)
Net Income -345.22
Cash from Operations -373.20
Cash from Investing 157.66
Cash from Financing 200.87
Net change in Cash -3.87
Free Cash Flow -362.86
Particulars MAR 2024 (Values in Cr)
Net Income -388.10
Cash from Operations -425.31
Cash from Investing 391.11
Cash from Financing 42.79
Net change in Cash 4.47
Free Cash Flow -398.80
Particulars MAR 2023 (Values in Cr)
Net Income -222.58
Cash from Operations -74.48
Cash from Investing -548.27
Cash from Financing 616.75
Net change in Cash -0.64
Free Cash Flow -59.09
Particulars MAR 2022 (Values in Cr)
Net Income -203.39
Cash from Operations -212.77
Cash from Investing -29.16
Cash from Financing 229.32
Net change in Cash -8.07
Free Cash Flow -180.09
Particulars MAR 2021 (Values in Cr)
Net Income -151.13
Cash from Operations -150.26
Cash from Investing 1.56
Cash from Financing 159.28
Net change in Cash 8.95
Free Cash Flow -144.26
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.80 13.14 1.53 243.69 23.12 38.85
BLISS GVS PHARMA LTD. 486.60 39.50 4.32 5160.70 118.35 493.70
CIPLA LTD 1353.85 28.73 3.17 109370.14 1165.55 1672.20
FERMENTA BIOTECH LIMITED 338.20 14.92 2.44 995.36 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.80 22.24 4.09 243.69 23.12 38.85
AMRUTAJAN HEALTH LTD 546.70 24.50 4.26 1580.54 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8406.60 109.79 24.07 21016.50 7630.00 9850.00
BLISS GVS PHARMA LTD. 486.60 52.49 4.46 5160.70 118.35 493.70

SUN PHARMA ADV.RES.CO.LTD shareholding pattern

Holding
31.76%
65.67%
2.47%
0.09%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

SUN PHARMA ADV.RES.CO.LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
236.64 -0.58 redarrow
red-green-graph indicator
1 Bearish
15 Bullish
  • 5 Days 236.10
  • 26 Days 210.90
  • 10 Days 229.50
  • 50 Days 190.30
  • 12 Days 227.00
  • 100 Days 169.10
  • 20 Days 217.40
  • 200 Days 158.40
239.93 PIVOT
First Support 234.16 First Resistance 243.85 Second Support 230.24 Second Resistance 249.62 Third Support 224.47 Third Resistance 253.54
RSI 67.50 ADX 40.73 MACD 16.34 Williams % R -25.53 Commodity Channel Index (CCI) 111.93
Date 2026-06-19 Week 1452558.00 Same Day 605108.00 Month 1844484.00
1 Year 1.86 3 Year 1.35
Over 1 Month
32.44% down
Over 1 Year
58.07% down
Over 3 Months
106.67% down
Over 3 Years
6.57% down
Over 6 Months
65.54% down
Over 5 Years
0.46% down

SUN PHARMA ADV.RES.CO.LTD Corporate Actions

Top Gainers

Top Losers

About the Company

Sun Pharmaceutical Industries Limited was founded in 1983 by Dilip Shanghvi. The company began operations with a small portfolio of psychiatry medicines and later expanded into branded generics, speciality medicines, active pharmaceutical ingredients and global pharmaceutical markets. Sun Pharma is headquartered in Mumbai, Maharashtra. The company is listed on the National Stock Exchange under the ticker SUNPHARMA and on the Bombay Stock Exchange under the code 524715.

Sun Pharma operates in the pharmaceutical sector and manufactures, develops and markets medicines across chronic and acute therapy areas. Its business includes generic formulations, branded generics, speciality products, APIs and over-the-counter products. The company has a presence in more than 100 countries and is supported by a global manufacturing network. 

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Sun Pharma Advanced Research Company Ltd?

Answer Field

Sun Pharma Advanced Research Company Ltd share price is for NSE ₹ 234.92 & for BSE ₹ 235.20 as on Jun 23 2026 03:30 PM.

What is the Market Cap of Sun Pharma Advanced Research Company Ltd Share?

Answer Field

The market cap of Sun Pharma Advanced Research Company Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 23 2026 03:30 PM.

What is the 52 Week High and Low of Sun Pharma Advanced Research Company Ltd?

Answer Field

The 52 Week High and Low of Sun Pharma Advanced Research Company Ltd for NSE is ₹ 253.17 and ₹ 108.00 and for BSE is ₹ 252.95 and ₹ 108.20.

What is 1 year return for Sun Pharma Advanced Research Company Ltd?

Answer Field

The 1 year returns on the stock has been 51.96%.

What is the P/E Ratio of Sun Pharma Advanced Research Company Ltd Share?

Answer Field

As on Jun 23 2026 03:30 PM the price-to-earnings (PE) ratio for Sun Pharma Advanced Research Company Ltd share is 4.97.

What is the PB ratio of Sun Pharma Advanced Research Company Ltd Share?

Answer Field

As on Jun 23 2026 03:30 PM, the price-to-book (PB) ratio for Sun Pharma Advanced Research Company Ltd share is 41.09.

How to Buy Sun Pharma Advanced Research Company Ltd Share?

Answer Field

You can trade in Sun Pharma Advanced Research Company Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Sun Pharma Advanced Research Company Ltd Share on Bajaj Broking App?

Answer Field

To buy Sun Pharma Advanced Research Company Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Sun Pharma Advanced Research Company Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image
Get Free Demat Account*
+91
close-img
Authorise with OTP
Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|